This is filed to report the serious injuries.It was reported through a research article identifying mitraclip that may be related to the following: patient deaths, recurrent mitral regurgitation, leaflet perforation, cardiogenic shock, stroke, myocardial infarction, heart failure, pneumonia, atrial perforation, infection, pseudoaneurysm, fistula, bleeding, renal failure, medical intervention, mitral valve replacement, and hospitalization.Device issues include, single leaflet device attachment (slda), and inability to grasp the leaflets.Details are listed in the article, titled ¿acute and midterm outcome after mitraclip therapy in patients with severe mitral regurgitation and left ventricular dysfunction.¿.
|
The devices were not returned for analysis.A review of the lot histories could not be performed as the lot numbers and part numbers are unknown.A query of the echo analytic reporting system (ears) complaint-handling database to determine similar incidents could not be performed as the lot numbers and the part numbers are unknown.The reported patient effects of stroke (cerebrovascular accident), atrial septal defect requiring intervention (atrial perforation), infection, fistula, worsening heart failure, worsening mitral regurgitation, tissue damage, myocardial infarction, cardiogenic shock, edema, renal insufficiency, pseudoaneurysm, and hemorrhage, as listed in the mitraclip nt system instructions for use, are known possible complications associated with mitraclip procedures.Based on the limited available information, a cause for the reported patient effects of cerebrovascular accident, atrial perforation (percutaneous intervention), infection, fistula, heart failure, worsening mitral regurgitation, tissue damage, myocardial infarction, cardiogenic shock, pulmonary edema, renal failure (dialysis required), pseudoaneurysm, hemorrhage, additional therapy/non-surgical treatment (blood transfusion, additional procedure mitral valve, iabp, pti), surgical procedure (major surgery) and hospitalization cannot be determined.There is no indication of a product issue with respect to manufacture, design or labeling.
|